摘要
当前，在我国提交的有关临床药物性肝损伤（DILI）研究及相关文献中，相关的诊断标准采用非常混乱，使这些研究的结果、结论和经验无从比较和推广，因此，有必要认真回顾诊断量表的发展历史，统一标准和相关认识。RUCAM量表白1993年问世以来，不论是在文献中，还是在对有可能引起DILI的药物调控决策方面，已广泛用于评估因果关系，为临床医师提供一种诊断DILI的有益分析构架。除非将来发现具有明确诊断意义的标志物，目前仍应采用RUCAM作为DILI的因果关系评估和辅助诊断量表。
Currently, the diagnostic criteria for drug-induced liver injury （DILI） used in the clinical studies and related literature in China are very confusing, making it difficult to compare and extend the use of the results, conclusions, and experience of these studies. Therefore, it is necessary to carefully review the developmental history of diagnostic scales and unify the diagnostic criteria and related knowledge of DILI. Since its publication in 1993, Roussel Uclaf Causality Assessment Method （RUCAM） scale has been widely used to assess the causality between drugs and liver injury, both in DILI studies and decisions on the regulation of drugs which may cause liver injury, in order to provide a useful analytical framework for clinical physicians in the diagnosis of DILI. At present, RUCAM scale should still be used to assess causality and assist diagnosis, unless markers with diagnostic significance are found in future.
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2016年第11期801-803,共3页
Chinese Journal of Hepatology
